Home › Research › Prevention and risk
Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts
Betthauser TJ, Bilgel M, Koscik RL, Jedynak BM, An Y, Kellett KA, Moghekar A, Jonaitis EM et al.. Brain : a journal of neurology, 2022-11-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Cox regression and accelerated failure time models were used to investigate whether sex, apolipoprotein E genotype and e4 carriage were associated with amyloid onset age in all cohorts. Cox regression was used to investigate whether apolipoprotein E (e4 carriage and e3e3, e3e4, e4e4 genotypes), sex or age of amyloid onset were associated with the time from amyloid onset to impairment onset (global clinical dementia rating ≥1) in a subset of 595 ADNI participants that were not impaired before amyloid onset. Sex and apolipoprotein E e4 carriage were not associated with PET-measured amyloid accumulation rates. Apolipoprotein E genotype and e4 carriage, but not sex, were associated with amyloid onset age such that e4 carriers became amyloid positive at an earlier age compared to non-carriers, and greater e4 dosage was associated with an earlier amyloid onset age. In the ADNI, e4 carriage, being female and a later amyloid onset age were all associated with a shorter time from amyloid onset to impairment onset. These findings demonstrate the feasibility of modelling longitudinal amyloid accumulation to enable individualized estimates of amyloid onset age from amyloid PET imaging.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. This study modelled amyloid onset age from PET imaging and found that apolipoprotein E e4 carriers became amyloid positive at an earlier age, with greater e4 dosage linked to earlier onset. It also found that e4 carriage, being female, and later amyloid onset age were associated with a shorter time from amyloid onset to impairment, but it did not test any treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Betthauser, T. J., Bilgel, M., Koscik, R. L., Jedynak, B. M., An, Y., Kellett, K. A., et al. (2022). Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain : a journal of neurology. https://doi.org/10.1093/brain/awac213
Vancouver
Betthauser TJ, Bilgel M, Koscik RL, Jedynak BM, An Y, Kellett KA, et al. Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain : a journal of neurology. 2022. doi:10.1093/brain/awac213. PMID: 35856240.
BibTeX
@article{betthauser2022-35856240,
author = {Betthauser, T. J. and Bilgel, M. and Koscik, R. L. and Jedynak, B. M. and An, Y. and Kellett, K. A. and Moghekar, A. and Jonaitis, E. M. and others},
title = {{Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts}},
journal = {Brain : a journal of neurology},
year = {2022},
doi = {10.1093/brain/awac213},
pmid = {35856240},
url = {https://doi.org/10.1093/brain/awac213}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Cox regression and accelerated failure time models were used to investigate whether sex, apolipoprotein E genotype and e4 carriage were associated with amyloid onset age in all cohorts.
- Cox regression was used to investigate whether apolipoprotein E (e4 carriage and e3e3, e3e4, e4e4 genotypes), sex or age of amyloid onset were associated with the time from amyloid onset to impairment onset (global clinical dementia rating ≥1) in a subset of 595 ADNI participants that were not impaired before amyloid onset.
- Sex and apolipoprotein E e4 carriage were not associated with PET-measured amyloid accumulation rates.
- Apolipoprotein E genotype and e4 carriage, but not sex, were associated with amyloid onset age such that e4 carriers became amyloid positive at an earlier age compared to non-carriers, and greater e4 dosage was associated with an earlier amyloid onset age.
- In the ADNI, e4 carriage, being female and a later amyloid onset age were all associated with a shorter time from amyloid onset to impairment onset.
Why it matters
This study modelled amyloid onset age from PET imaging and found that apolipoprotein E e4 carriers became amyloid positive at an earlier age, with greater e4 dosage linked to earlier onset. It also found that e4 carriage, being female, and later amyloid onset age were associated with a shorter time from amyloid onset to impairment, but it did not test any treatment.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 67/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 64 of the 96 points we could judge it on, which is 67 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Brain : a journal of neurology) |
| Journal's citation record | 4 / 4 | Brain: journal h-index 503 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 136 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 22.7 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 4 / 6 | Cited 15.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 20 other studies in this library |
| Still being cited | 3 / 4 | Cited 117 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 3 / 3 | National Institutes of Health: institution h-index 2,723 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35856240) |
| Free to read | 2 / 2 | Free to read |
| Points | 64 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 64 of the 96 points we could judge it on is 67 out of 100. |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 28.
Later studies that cite this one
20 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Prevention and risk from nearby years
Also in Prevention and risk
265 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.